Cerapedics commenced full commercial availability of i-FACTOR®+ MATRIX for surgical implantation in Canada. This follows Health Canada approval in September.
i-FACTOR+ MATRIX uses small proprietary peptide technology supports bone growth through cell attraction, attachment and activation. i-FACTOR Peptide Enhanced Bone Graft was approved in the EU in 2008 and Australia in 2010 for orthopedic applications in the spine and extremities. In the U.S., i-FACTOR received premarket approval in 2015 for use in single-level anterior cervical fusion.
“We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of Cerapedics. “Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.”
Cerapedics commenced full commercial availability of i-FACTOR®+ MATRIX for surgical implantation in Canada. This follows Health Canada approval in September.
i-FACTOR+ MATRIX uses small proprietary peptide technology supports bone growth through cell attraction, attachment and activation. i-FACTOR Peptide Enhanced Bone Graft was...
Cerapedics commenced full commercial availability of i-FACTOR®+ MATRIX for surgical implantation in Canada. This follows Health Canada approval in September.
i-FACTOR+ MATRIX uses small proprietary peptide technology supports bone growth through cell attraction, attachment and activation. i-FACTOR Peptide Enhanced Bone Graft was approved in the EU in 2008 and Australia in 2010 for orthopedic applications in the spine and extremities. In the U.S., i-FACTOR received premarket approval in 2015 for use in single-level anterior cervical fusion.
“We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of Cerapedics. “Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
